New drug PEEL-224 enters first human tests for advanced cancers

NCT ID NCT05329103

Recruiting now Disease control Sponsor: Peel Therapeutics Inc Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study is testing a new drug called PEEL-224 in 65 people with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers will also look for signs that the drug can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PEEL-224 (a drug given by infusion) and FOLF+B (a combination of chemotherapy drugs and bevacizumab)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced solid tumors that have not responded to standard therapies.
What could go wrong: This is a very early, first-in-human study with only 65 participants. The drug may not shrink tumors or could cause serious side effects. Success is far from guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Show contact details

Locations

Abramson Cancer Center at Pennsylvania Hospital
COMPLETED

Philadelphia, Pennsylvania, 19106, United States
Carolina BioOncology Institute
COMPLETED

Huntersville, North Carolina, 28078, United States
HonorHealth Research Institiute
RECRUITING

Scottsdale, Arizona, 85258, United States

Contact Email: •••••@•••••
Huntsman Cancer Institute, University of Utah
RECRUITING

Salt Lake City, Utah, 84112, United States
Mary Crowley Cancer Research
COMPLETED

Dallas, Texas, 75230, United States
NEXT Virginia
RECRUITING

Fairfax, Virginia, 22031, United States
Rhode Island Hospital
RECRUITING

Providence, Rhode Island, 02903, United States
Stanford Cancer Center
ACTIVE_NOT_RECRUITING

Palo Alto, California, 94305, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.